AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AMGEN INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$424.94−7.55 (-1.75%)
Close on Oct 19, 2026
- Market cap
- $231.17B
- P/E (TTM)
- 26.4
- Dividend yield
- 2.27%
AMGEN INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $35.15B | $32.03B | $26.91B | $24.80B | $24.30B | $24.24B | $22.20B | $22.53B | $21.80B | $21.89B | 95.6% | +9.7% |
| Other products | $7.26B | $5.63B | $4.70B | $5.05B | $5.71B | $5.37B | $4.74B | $5.57B | $2.58B | $3.16B | 19.8% | +29.0% |
| Prolia | $4.41B | $4.37B | $4.05B | $3.63B | $3.25B | $2.76B | $2.67B | $2.29B | $1.97B | $1.64B | 12.0% | +0.9% |
| Repatha | $3.02B | $2.22B | $1.64B | – | – | – | – | – | $319.00M | $141.00M | 8.2% | +35.7% |
| Otezla | $2.27B | $2.13B | $2.19B | $2.29B | $2.25B | $2.20B | $178.00M | $0 | – | – | 6.2% | +6.5% |
| ENBREL | $2.23B | $3.32B | $3.70B | $4.12B | $4.47B | $5.00B | $5.23B | $5.01B | $5.43B | $5.97B | 6.1% | -32.9% |
| EVENITY | $2.10B | $1.56B | $1.16B | $787.00M | – | – | – | – | – | – | 5.7% | +34.4% |
| XGEVA | $2.08B | $2.23B | $2.11B | $2.01B | $2.02B | $1.90B | $1.94B | $1.79B | $1.58B | $1.53B | 5.7% | -6.3% |
| TEPEZZA | $1.90B | $1.85B | $448.00M | $0 | $0 | – | – | – | – | – | 5.2% | +2.8% |
| Other revenues | $1.60B | $1.40B | $1.28B | $1.52B | $1.68B | $1.18B | $1.16B | $1.21B | $1.05B | $1.10B | 4.4% | +14.7% |
| BLINCYTO | $1.56B | $1.22B | $861.00M | $583.00M | $472.00M | – | – | – | $175.00M | $115.00M | 4.2% | +28.2% |
| Nplate | $1.52B | $1.46B | $1.48B | $1.31B | $1.03B | $850.00M | $795.00M | – | $642.00M | $584.00M | 4.1% | +4.7% |
| TEZSPIRE | $1.48B | $972.00M | $567.00M | $170.00M | – | – | – | – | – | – | 4.0% | +52.1% |
| KYPROLIS | $1.41B | $1.50B | $1.40B | – | – | – | – | – | – | – | 3.8% | -6.1% |
| Aranesp | $1.39B | $1.34B | $1.36B | $1.42B | $1.48B | $1.57B | $1.73B | $1.88B | $2.05B | $2.09B | 3.8% | +3.5% |
| KRYSTEXXA | $1.34B | $1.19B | $272.00M | $0 | $0 | – | – | – | – | – | 3.6% | +13.1% |
| Vectibix | $1.18B | $1.05B | $984.00M | $893.00M | $873.00M | – | – | – | $642.00M | $611.00M | 3.2% | +12.4% |
| Other [Member] | – | – | – | – | – | – | – | – | $256.00M | $250.00M | – | – |
| Neulasta (pegfilgrastim) [Member] | – | – | – | $1.13B | $1.73B | $2.29B | $3.22B | $4.48B | $4.53B | $4.65B | – | – |
| EPOGEN (epoetin alfa) [Member] | – | – | – | – | – | – | $867.00M | $1.01B | $1.10B | $1.28B | – | – |
| Sensipar / Mimpara (cinacalcet) [Member] | – | – | – | – | – | – | $551.00M | $1.77B | $1.72B | $1.58B | – | – |
| NEUPOGEN [Member] | – | – | – | – | – | – | – | – | $549.00M | $765.00M | – | – |
| KYPROLIS | – | $1.50B | $1.40B | $1.25B | $1.11B | $1.07B | $1.04B | $968.00M | $835.00M | $692.00M | – | – |
| Repatha | – | $2.22B | $1.64B | $1.30B | $1.12B | $887.00M | $661.00M | $550.00M | – | – | – | – |
| EVENITY | – | – | $1.16B | $787.00M | $530.00M | $350.00M | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $26.42B | $23.86B | $19.81B | $18.60B | $18.19B | $18.50B | $17.22B | $18.36B | $18.03B | $18.33B | 71.9% | +10.7% |
| ROW | $10.33B | $9.56B | $8.38B | $7.73B | $7.79B | $6.93B | $6.14B | $5.39B | $4.82B | $4.67B | 28.1% | +8.1% |
| Rest of the world (ROW) [Member] | – | – | – | – | – | – | – | – | $4.82B | $4.67B | – | – |
From the segment and revenue-disaggregation notes of Amgen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.